Form 4: Eikon Therapeutics Director Frazier Acquires Stock Options

Eikon Therapeutics Director Kenneth C. Frazier has acquired 25,873 stock options with an exercise price of $14.88, vesting monthly over four years.

Summary

• Kenneth C. Frazier, a Director at Eikon Therapeutics, Inc. (EIKN), acquired 25,873 stock options.
• The options have an exercise price of $14.88 per share.
• The vesting schedule dictates that 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months.
• Vesting is subject to Mr. Frazier's continued service through each vesting date.
• The earliest transaction date for this acquisition was March 2, 2026, with an expiration date of March 1, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine compensation that aligns director interests with shareholder value creation, without indicating any immediate operational or financial shifts.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.

Future Outlook

The vesting schedule over 48 months indicates an expectation of continued service from Kenneth C. Frazier as a Director, aligning his long-term incentives with the company's performance.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to incentivize long-term commitment and performance.

Comparison to Industry Standards

• Without specific data on Eikon Therapeutics' peer group or typical director compensation structures for similar-stage biotech companies, a direct comparison of the option grant size and exercise price to industry standards is not feasible from this filing alone.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with the company's stock performance, potentially benefiting shareholders if the company's value increases.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The options will vest monthly over the next 48 months, contingent on Kenneth C. Frazier's continued service.

Key Dates

Keywords

Eikon Therapeutics, EIKN, Kenneth C. Frazier, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Compensation